Theriva Biologics Inc Dossier
Qualitative Analysis
Business overview
Theriva Biologics, Inc. (NYSE American: TOVX) is a diversified, clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat cancer and related diseases in areas of high unmet need. The company's primary asset is VCN-01 (zabilugene almadenorepvec), a systemically administered oncolytic adenovirus designed to selectively replicate within tumor cells and degrade the tumor stroma, which acts as a physical and immunosuppressive barrier to cancer treatments. Theriva transitioned its strategic focus to oncology following its acquisition of Theriva Biologics, S.L. (formerly VCN Biosciences, S.L.) in March 2022. Beyond VCN-01, the company's pipeline includes VCN-11, which utilizes its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system, and SYN-004 (ribaxamase), an oral prophylactic therapy designed to prevent acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing resources toward the clinical development of lead candidate VCN-01 for pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma.
Expected impact: Aims to advance VCN-01 to pivotal Phase 3 development in PDAC and Phase 2/3 in retinoblastoma.
Out-licensing non-core gastrointestinal assets, such as SYN-020, to strategic partners to derive value and reduce direct R&D expenditures.
Expected impact: Reduces R&D burn while retaining upside through potential milestone payments of up to $38 million and royalties.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Monetizes SYN-020, a non-core asset, allowing Theriva to focus resources on its oncology pipeline while retaining financial upside.
Terms: Theriva received a $300,000 upfront payment and is eligible for up to $16 million in development and regulatory milestones, up to $22 million in sales milestones, and tiered single-digit royalties on net product sales.